Several medical societies supported extending Medicare coverage for TAVR to patients with asymptomatic aortic stenosis, but ...

Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial readout, as global demand for the technology increases. The company ...

Edwards pushes CMS to expand Medicare TAVR coverage to asymptomatic patients, sparking controversy among physicians over ...

SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company that develops and provides patient-focused innovations for heart conditions, specializing in structural heart disease ...

Edwards Lifesciences stock surged Wednesday — and retook both its key moving averages — after beating fourth-quarter forecasts for its heart-valve replacements. Please watch the video at Investors.com ...

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...